Tirzepatide
The first approved drug that simultaneously activates two different incretin receptors — GIP and GLP-1 — rather than just one, like older drugs in this class. In head-to-head trials it produced greater weight loss than semaglutide, at the cost of a very similar side-effect profile.
Number of studies
4
Safety
Requires caution
Time to effects
Reduced appetite is sometimes noticeable within the first few weeks, but meaningful, measurable weight loss develops gradually over several months, and the full effect assessed in SURMOUNT-1 was measured after 72 weeks (about 1.5 years) of regular treatment.
Monthly cost
ok. 1000–1600 zł/miesiąc
Price in Poland
ok. 1000–1600 zł za opakowanie miesięczne, zależnie od dawki i apteki
Who it's for
Cena jest wyższa niż większości starszych leków z klasy GLP-1, bez pełnej refundacji we wskazaniu otyłościowym w Polsce w większości przypadków — warto zweryfikować aktualne zasady refundacji przed rozpoczęciem terapii.
Indicative prices for the Polish market — we don't point to specific retailers; the real price depends on the manufacturer, form and place of purchase.
Table of contents
TL;DR
The first approved drug that simultaneously activates two different incretin receptors — GIP and GLP-1 — rather than just one, like older drugs in this class. In head-to-head trials it produced greater weight loss than semaglutide, at the cost of a very similar side-effect profile.
- →Body-weight reduction averaging 16.0–22.5% by week 72 of treatment, depending on dose (SURMOUNT-1 trial)
- →Significantly greater weight loss and waist-circumference reduction than the maximum dose of semaglutide in a direct head-to-head comparison (SURMOUNT-5)
- →Significant HbA1c reduction in people with type 2 diabetes, with a higher proportion reaching normoglycemia than with older incretin drugs
| Active substance | Tirzepatide — a synthetic, dual GIP and GLP-1 receptor agonist |
|---|---|
| Brand names | Mounjaro (type 2 diabetes), Zepbound (obesity/overweight) — the same molecule |
| Drug class | Incretin mimetic; the first approved dual GIP/GLP-1 agonist |
| Approved indications | Type 2 diabetes (FDA 2022), chronic obesity/overweight management (FDA 2023) |
| Route of administration | Once-weekly subcutaneous injection, single-use autoinjector |
| Research level | Strong — the SURMOUNT and SURPASS programs, randomized phase 3 trials |
| Status | Prescription drug; requires medical supervision and gradual dose escalation |
Understand
Overview
Tirzepatide is a synthetic peptide sold under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for obesity and overweight with related conditions) — the same chemical molecule marketed under two names for two indications, much like semaglutide as Ozempic and Wegovy. What sets tirzepatide apart from earlier GLP-1 receptor agonists (semaglutide, liraglutide) isn't a minor refinement of the same molecule, but a change in the mechanism itself: tirzepatide is the first approved drug to simultaneously activate two different incretin hormone receptors — the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide) — in a single molecule, instead of only one of them.
For decades, GIP was treated in the context of type 2 diabetes almost as a research dead end — in people with chronic hyperglycemia, the GIP receptor shows partial desensitization, which led to the conclusion that GIP alone had limited therapeutic value in this population. The breakthrough came when it was discovered that combining GIP agonism with GLP-1 agonism in a single molecule produces a synergistic effect exceeding the sum of either mechanism alone — both for glycemic control and, what turned out to matter more clinically and commercially, for weight loss. Tirzepatide was pharmacologically engineered as an 'imbalanced' agonist — it mimics native GIP closely at the GIP receptor but is a weaker agonist than native GLP-1 at the GLP-1 receptor, which paradoxically translates into less desensitization of the GLP-1 receptor and more durable signaling over time, discussed further in the mechanism section.
The FDA first approved tirzepatide in May 2022 as Mounjaro for type 2 diabetes, and in November 2023, under the same SURMOUNT clinical trial program, as Zepbound for chronic weight management in people with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The drug requires a prescription and is given as a once-weekly subcutaneous injection via an autoinjector, with gradual dose escalation from 2.5 mg up to a maximum of 15 mg weekly.
The scale of effect tirzepatide showed in registration trials was large enough to prompt a direct head-to-head comparison against semaglutide — until then the most effective drug in this class. The SURMOUNT-5 trial found a statistically significant advantage for tirzepatide over semaglutide in weight loss among the same type of patients, observed over the same period using the same methods — a rare situation in obesity pharmacology, where results are usually compared across separate trials with different designs rather than within one trial built for direct comparison.
Despite its higher efficacy, tirzepatide's side-effect profile is largely similar to semaglutide and other incretin-mimetic drugs — gastrointestinal complaints from slowed gastric emptying dominate, and the rare but serious risks (pancreatitis, biliary disease) are of a similar nature. This isn't a drug that offers higher efficacy 'for free' — the risk-benefit balance still requires the same individual clinical judgment described in more depth in our article on semaglutide's side effects; most of those considerations apply here too.
It's also worth noting a phenomenon that has grown alongside tirzepatide's popularity: 'compounded' preparations, produced by compounding pharmacies without the full quality and dosing control typical of an approved drug, often sold outside standard medical supervision during shortages of the original product. The FDA has repeatedly warned about these preparations due to unconfirmed purity, potency, and sterility — a topic we return to in the variants section.
History of use
The idea of therapeutically exploiting GIP was treated with skepticism for decades — studies from the 1990s and 2000s showed that people with type 2 diabetes respond much more weakly to native GIP than healthy people, interpreted as receptor resistance that made GIP a poor drug candidate. The breakthrough came when research teams (including Eli Lilly scientists) showed that combining GIP agonism with GLP-1 agonism in one properly engineered molecule reverses this resistance and produces a synergistic, not neutralizing, effect. Tirzepatide, developed under the code name LY3298176, went through the SURPASS (type 2 diabetes) and SURMOUNT (obesity) clinical trial programs, gaining FDA approval as Mounjaro in May 2022 and as Zepbound in November 2023 — one of the fastest paths from mechanistic concept to two separate clinical approvals in modern metabolic pharmacology.
Mechanism of action
Tirzepatide is a 39-amino-acid peptide engineered to bind and activate two distinct G-protein-coupled receptors: the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). Both receptors are present on pancreatic beta cells, where their activation enhances glucose-dependent insulin secretion, and in the central nervous system, including hypothalamic nuclei that regulate satiety. A key, unusual pharmacological feature of tirzepatide is that it's described in the literature as an 'imbalanced agonist' — at the GIP receptor it behaves almost identically to native GIP, while at the GLP-1 receptor it's a distinctly weaker agonist than native GLP-1. This apparently unfavorable trade-off has an important practical consequence: weaker GLP-1 receptor activation causes less desensitization and internalization of the receptor, allowing more sustained signaling over repeated, weekly dosing instead of a rapid 'burnout' of the receptor response.
At the level of clinical effect, GLP-1 receptor activation accounts for mechanisms already familiar from semaglutide: slowed gastric emptying, increased satiety via action on centers in the hypothalamus and brainstem, and glucose-dependent increases in insulin secretion alongside reduced glucagon secretion. This slowed gastric emptying is the main mechanism behind the most common side effects — nausea, vomiting, and diarrhea — in a way analogous to what's described in our semaglutide article.
The separate, additional contribution of the GIP receptor is less intuitive and still being clarified in basic research, but preclinical data point to several possible synergy mechanisms: GIPR activation in adipose tissue may improve adipocytes' ability to store lipids in a metabolically favorable way (limiting visceral and ectopic fat accumulation), and animal models have shown increased energy expenditure with simultaneous activation of both receptors compared to GLP-1R activation alone. Combined with the fact that GIP and GLP-1 receptors coexist in many of the same hypothalamic appetite-regulating centers, simultaneous activation of both appears to produce a supra-additive, not merely additive, reduction in food intake — which practically translates into greater weight loss than a single GLP-1 agonist, observed directly in the SURMOUNT-5 head-to-head trial.
Pharmacokinetically, tirzepatide has a half-life of roughly five days, which, like semaglutide, allows once-weekly dosing and a stable serum concentration between doses. The drug is metabolized through proteolysis of the peptide backbone and beta-oxidation of the fatty-acid chain attached to the molecule (which extends albumin binding and thus half-life), rather than through the main hepatic or renal pathways typical of small molecules — relevant when assessing drug interactions.
Binding to two receptors
Tirzepatide binds and activates both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) simultaneously, unlike older drugs that activate only the latter.
Imbalanced agonism
It acts like native GIP at GIPR but more weakly than native GLP-1 at GLP-1R — this reduces GLP-1 receptor desensitization and extends signaling durability between doses.
Slowed gastric emptying
GLP-1R activation slows stomach motility, enhancing satiety — the same mechanism behind the dominant side effects.
Action on satiety centers
Both receptors are present in hypothalamic appetite-regulating nuclei, and their simultaneous activation produces a greater effect than the sum of each alone.
Glucose-dependent insulin secretion
Activation of both receptors on pancreatic beta cells boosts insulin secretion only when glucose is elevated, limiting hypoglycemia risk in monotherapy.
Effect on fat tissue
Preclinical data suggest GIPR activation in adipocytes may improve metabolically favorable lipid storage — a mechanism absent with GLP-1 agonism alone.
Evidence: strong — based on 4 studies in this database.
Benefits
Common myths
MythTirzepatide is simply a stronger version of semaglutide, working through the same mechanism at a higher dose.
FactTirzepatide activates two different incretin receptors (GIP and GLP-1), while semaglutide acts only on the GLP-1 receptor — this is a distinct pharmacological mechanism, not just a matter of dose strength of the same molecule.
MythSince tirzepatide is newer and more effective, it's automatically safer than semaglutide.
FactThe side-effect profile is largely analogous — the same gastrointestinal complaints and the same rare, serious risks (pancreatitis, biliary disease) dominate. Higher efficacy doesn't mean lower risk.
MythCompounded tirzepatide preparations are a safe, cheaper alternative to the original drug.
FactThe FDA has repeatedly warned about such preparations due to unconfirmed purity, actual potency, and sterility — they don't undergo the same quality control as Mounjaro or Zepbound.
Forms & variants
Tirzepatide comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Mounjaro
The brand name for tirzepatide approved for type 2 diabetes, dosed at 2.5–15 mg weekly.
Best for: People with type 2 diabetes needing intensified pharmacological treatment
Zepbound
The same molecule as Mounjaro, separately approved for chronic obesity and overweight with comorbidities.
Best for: People with BMI ≥30, or ≥27 with a weight-related comorbidity
Compounded preparations
Non-standardized preparations made by compounding pharmacies, outside the full quality control typical of an approved drug — the FDA has repeatedly warned about unknown purity, potency, and sterility of these products.
Best for: Not a recommended alternative — the risk outweighs the potential benefit of a lower price
Check your profile
Not sure which supplements actually make sense for you?
Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
Semaglutide activates only the GLP-1 receptor. Tirzepatide simultaneously activates the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide) — a second incretin hormone long considered of limited therapeutic use in type 2 diabetes. Combining both mechanisms in a single molecule produces a synergistic effect, stronger than the sum of each alone, which translated in practice into higher weight-loss efficacy in the SURMOUNT-5 head-to-head trial.
It isn't just a marketing claim — SURMOUNT-5, designed specifically as a direct comparison, found a statistically significant advantage for tirzepatide: -20.2% weight loss vs. -13.7% for semaglutide in the same population, observed over the same period using the same methods.
Yes, the side-effect profile largely overlaps — gastrointestinal complaints (nausea, diarrhea, vomiting, constipation) from slowed gastric emptying dominate, and the rare, serious risks (pancreatitis, biliary disease) are of similar nature and frequency as with other drugs in this class.
Yes, to a similar degree — DEXA analysis in SURMOUNT-1 showed that while most of the lost weight (about 74–75%) is fat tissue, part of the loss includes lean body mass too. We discuss this phenomenon, including practical mitigation strategies, more fully in our article on GLP-1 drugs and muscle mass loss.
The SURMOUNT-4 trial showed that participants switched to placebo after an initial treatment period experienced significant weight regain, while those continuing tirzepatide achieved further weight loss. We discuss this mechanism, common to the entire GLP-1 drug class, more fully in our article on the yo-yo effect after stopping GLP-1 treatment.
This isn't a recommended option. The FDA has repeatedly warned that compounded preparations don't undergo the same purity, potency, and sterility controls as approved Mounjaro or Zepbound, and reports of adverse events linked to dosing errors with such preparations are a real concern.
The drug is approved for treating type 2 diabetes and obesity or overweight with specific comorbidities, at defined BMI thresholds. Use outside these indications isn't supported by the registration trials, which recruited participants meeting these criteria, and carries the same real side-effect risks without a clearly documented benefit.
Dosage & timing
Typical dose
Start at 2.5 mg weekly, gradual escalation every 4 weeks to a maintenance dose of 5, 7.5, 10, 12.5, or a maximum of 15 mg weekly, depending on tolerance and treatment goal
Form
Solution for subcutaneous injection in a single-use autoinjector (Mounjaro, Zepbound)
Dosing is informational and reflects the ranges used in the cited studies — it does not replace consulting a doctor or pharmacist.
Best times to take it
- Once weekly, on the same day, regardless of meals — the day can be changed if at least 3 days have passed since the last dose
- Rotate injection sites (abdomen, thigh) to limit local irritation
- Dose escalation no more often than every 4 weeks — speeding up the schedule increases the risk of severe gastrointestinal discomfort
- A missed dose can be given up to 4 days after the scheduled time; after that, wait for the next scheduled day
Safety
Side effects & contraindications
Possible side effects
Nausea, diarrhea, vomiting, and constipation — the most common side effects, dependent on the pace of dose escalation, with a mechanism analogous to semaglutide's
Biliary disease, including gallstones — elevated risk linked to rapid, substantial weight loss itself, not just the drug
Rarely: acute pancreatitis — requires immediate consultation for severe abdominal pain radiating to the back
Gastroparesis and delayed gastric emptying, especially relevant before procedures under general anesthesia
Injection-site reactions — redness, itching, rarely local allergic reactions
Hypoglycemia risk when combined with insulin or a sulfonylurea, even though tirzepatide itself acts glucose-dependently
A theoretical risk of thyroid C-cell tumors — a class warning based on rodent studies, not confirmed in humans so far, but resulting in an absolute contraindication in specific risk groups
Contraindications
Personal or family history of medullary thyroid carcinoma or MEN2 syndrome — an absolute contraindication, as with semaglutide
Pregnancy and breastfeeding — insufficient safety data
History of pancreatitis
Severe, chronic gastrointestinal disease, including diagnosed gastroparesis
Hypersensitivity to tirzepatide or other ingredients
An upcoming procedure under general anesthesia without prior discontinuation per anesthesiology guidelines
Interactions
Insulin and sulfonylureas — significantly increased hypoglycemia risk when combined, usually requiring a dose reduction of these drugs
Oral drugs requiring fast, predictable absorption — delayed gastric emptying can alter their absorption profile
Oral contraceptives — during episodes of significant vomiting or diarrhea (not from the drug itself), oral contraceptive efficacy may be reduced, with an additional barrier method recommended during such episodes
Warfarin and other narrow-therapeutic-index drugs — a theoretical risk of altered absorption warranting closer monitoring early in treatment
Alcohol — not a direct pharmacokinetic interaction, but it worsens stomach irritation and nausea risk during dose escalation
Is it worth taking?
Who it's for
- People with type 2 diabetes with inadequate glycemic control on other oral medications
- People with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity
- Patients for whom semaglutide proved insufficiently effective or poorly tolerated, after consulting a doctor
- People able to reliably follow a weekly injection schedule and gradual dose escalation under medical supervision
Not for
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome — an absolute contraindication, as with semaglutide
- Pregnancy and breastfeeding — insufficient safety data
- History of pancreatitis
- Severe, chronic gastrointestinal disease, including diagnosed gastroparesis
- Hypersensitivity to tirzepatide or other ingredients
- An upcoming procedure under general anesthesia without prior discontinuation per anesthesiology guidelines
Evidence
Worth knowing
Tirzepatide is the first approved drug to simultaneously activate two different incretin hormone receptors — GIP and GLP-1.
In a direct head-to-head comparison (SURMOUNT-5), it produced greater weight loss than the maximum dose of semaglutide: -20.2% vs. -13.7% at week 72.
About 74–75% of lost body weight in DEXA studies is fat tissue, not muscle.
After stopping the drug, placebo-group participants in SURMOUNT-4 regained a significant amount of weight, while those continuing treatment saw further weight loss.
Studies
At the 15 mg weekly dose, SURMOUNT-1 participants lost an average of 22.5% of body weight by week 72, and in the SURMOUNT-5 head-to-head trial, tirzepatide produced significantly greater weight loss than the maximum dose of semaglutide (-20.2% vs. -13.7%).
Jastreboff AM et al., NEJM, 2022; Aronne LJ et al., NEJM, 2025
Tirzepatide Once Weekly for the Treatment of Obesity
Strong evidenceJastreboff AM, Aronne LJ, Ahmad NN et al. (SURMOUNT-1 Investigators) · New England Journal of Medicine · 2022
A randomized, double-blind phase 3 trial in 2,539 adults with obesity or overweight (without type 2 diabetes) who received tirzepatide 5, 10, or 15 mg weekly or placebo for 72 weeks. Mean weight reduction was 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) versus 2.4% with placebo. At the highest dose, 63% of participants achieved at least 20% weight loss, versus 1.3% on placebo.
View studyTirzepatide as Compared with Semaglutide for the Treatment of Obesity
Strong evidenceAronne LJ, Horn DB, le Roux CW et al. (SURMOUNT-5 Investigators) · New England Journal of Medicine · 2025
The first published head-to-head trial comparing tirzepatide with semaglutide in adults with obesity without type 2 diabetes, randomized to the maximum tolerated dose of either drug for 72 weeks. Tirzepatide produced significantly greater weight loss (-20.2% vs. -13.7%; p<0.001) and waist-circumference reduction (-18.4 cm vs. -13.0 cm; p<0.001) than semaglutide in the same population.
View studyContinued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
Strong evidenceAronne LJ, Sattar N, Horn DB et al. · JAMA · 2024
Participants who achieved significant weight loss after 36 weeks of tirzepatide were randomized to continue the drug or switch to placebo for another 52 weeks. Those continuing tirzepatide achieved an additional 5.5 percentage points of weight loss, while the placebo group gained about 14% of weight relative to their weight at the start of the randomized withdrawal period — clearly showing the effect requires continued treatment.
View studyBody composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight
Moderate evidenceLook M, Dunn JP, Kushner RF et al. · Diabetes, Obesity and Metabolism · 2025
DEXA body-composition analysis in a 160-person SURMOUNT-1 subgroup found that by week 72, body weight fell 21.3%, fat mass 33.9%, and lean body mass 10.9% with tirzepatide. Of the weight lost, about 74% was fat mass and 26% lean mass — a proportion similar to the placebo group and to earlier semaglutide data.
View studySources & bibliography
- Jastreboff et al. 2022 — New England Journal of Medicine (SURMOUNT-1)
- Aronne et al. 2025 — New England Journal of Medicine (SURMOUNT-5)
- Aronne et al. 2024 — JAMA (SURMOUNT-4)
- FDA — Zepbound (tirzepatide) prescribing information
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.
268 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna studied molecular biology at the University of Warsaw, then spent eight years after her PhD in a lab researching the mechanisms of cellular aging and autophagy. She stumbled into science journalism almost by accident — frustrated by how easily her field's findings get oversimplified in the media, she started a blog explaining the biology of aging in plain language. That blog became the seed of VitMode. Today Anna oversees the entire editorial process, holding every piece to the same rigor her old lab demanded: primary sources, methodology checks, and honesty about the limits of the evidence. Outside work, she's a dedicated boulderer.
196 publications on this site
Related entries
4.6Obesity
A chronic disease linked to excess body fat — and its relationship with mortality, mapped in the largest available meta-analysis covering over 10 million participants, has the shape of a curve, not a straight line.
4.7Type 2 Diabetes
A chronic metabolic disease in which the body loses its ability to properly regulate blood glucose — and one of the few chronic diseases where a large randomized trial showed that lifestyle change alone can outperform a drug.
4.6Insulin Resistance
A state in which the body's cells respond more weakly to insulin, forcing the pancreas to produce ever-larger amounts of it — the most common, and largely reversible, precursor of type 2 diabetes.
4.7Testosterone
The primary anabolic hormone — its natural level depends heavily on sleep, resistance training, body composition and fat mass.
4.5SHBG (Sex Hormone-Binding Globulin)
A transport protein whose level determines how much testosterone is actually 'available' to tissues — without knowing SHBG, a total testosterone result alone can be misleading.
4.5Metformin
The most commonly prescribed drug for type 2 diabetes in the world — with a well-understood metabolic mechanism and an intensively studied, but still unproven, potential to slow aging.
4.5Minoxidil
A drug that was supposed to treat high blood pressure and instead became the longest-running over-the-counter hair-loss treatment in the world — discovered by accident, working through a completely different mechanism than finasteride, with one of the longest clinical-trial track records in dermatology.
4.4Statins
The best-researched class of LDL-cholesterol-lowering drugs, with one of the largest evidence bases in all of cardiology — yet still surrounded by numerous, largely unfounded fears.
Related articles
PoradnikiSemaglutide (Ozempic, Wegovy): What Do the Trials Actually Show About Side Effects?
Semaglutide, sold as Ozempic (diabetes) and Wegovy (weight loss), became within a few years one of the most prescribed and most talked-about drugs in the world. The promise — double-digit percentage weight loss without a restrictive diet — is backed by solid registration trials. Far less discussed is what those same trials showed on the other side of the ledger: who tolerates the drug poorly, what rare but serious complications large database analyses have flagged, and why part of the lost body weight isn't just fat.
September 4, 2026
PoradnikiGLP-1 Drugs and Muscle Mass Loss: What Do Body-Composition Studies Show?
Semaglutide and tirzepatide can reduce body weight by anywhere from the teens to the low twenties percent — a figure that dominates headlines. A second figure gets far less attention: what that lost weight is actually made of. DEXA body-composition studies show that part of it is lean body mass, including muscle — a phenomenon especially relevant for older patients and those who don't strength-train during treatment.
October 5, 2026
PoradnikiMicrodosing Ozempic: Is There Any Evidence Behind It?
On TikTok and at telehealth clinics, a promise circulates: semaglutide doses ten times lower than standard, supposedly taken for 'longevity' or 'mild appetite suppression without side effects.' The problem is that none of semaglutide's registration trials tested such doses for such indications — and the available dose-response data actually suggest the opposite.
October 5, 2026
PoradnikiThe Yo-Yo Effect After Stopping GLP-1 Drugs: What Does Extended Follow-Up Data Show?
Semaglutide and tirzepatide deliver spectacular weight-loss results — as long as they're used. Two independent extended-follow-up trials, one for semaglutide and one for tirzepatide, show what happens after stopping: most patients regain a significant portion of lost weight within a year, and the accompanying metabolic benefits partially reverse.
October 5, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.